Using specific small interfering RNA to inhibit ULK1 expression in ESCC cell lines can block cell proliferation, which supports the idea that blocking ULK1 may be a beneficial therapy for patients with EC 166. The gene discussed is ULK1; the disease is esophageal squamous cell carcinoma.